Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn’s Disease
Yu-Qing Guo, Yi-Ting Wang, Min Gao, Tao Liu, Li-Hong Huang, Sen Deng, Xiao-Yan Li, Meng-Dan Xu · 2026
Read Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn’s Disease by Yu-Qing Guo, Yi-Ting Wang, Min Gao, Tao Liu, Li-Hong Huang, Sen Deng, Xiao-Yan Li, Meng-Dan Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570625.txt.
Description
Yu-Qing Guo and co-authors build a 2026 forecast model for Crohn's disease patients whose drug stops working over time. Infliximab is a main therapy for moderate to severe Crohn's, but many patients lose response after first gaining it. The team studied 637 patients at one large center, fed many measures into nine learning methods, and judged each at one, two, and three years.
A gradient boosting model won, with accuracy that grew over the longer spans. Seven factors drove the risk, led by the drug level in blood during maintenance care. A survival-aware explanation method ranked those factors for each patient. The authors say the tool can flag high-risk patients early for closer watch.
Catalog record
| CREATOR | Yu-Qing Guo, Yi-Ting Wang, Min Gao, Tao Liu, Li-Hong Huang, Sen Deng, Xiao-Yan Li, Meng-Dan Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |